An AIDS Vaccine by 2007? Not Likely, Say Participants

May 18 marked the one-year anniversary of President Bill Clinton's pledge--some say more politically motivated than realistic--that there will be an AIDS vaccine by the year 2007. READY FOR PHASE III: Donald Francis of VaxGen is ready for Phase III trials of its AIDS vaccine to begin. The field of AIDS vaccine research has been and remains acrimonious. The basic researchers who insist on proof of immune response prior to large clinical trials disagree with the vaccine researchers whose experi

| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share


READY FOR PHASE III: Donald Francis of VaxGen is ready for Phase III trials of its AIDS vaccine to begin.
The field of AIDS vaccine research has been and remains acrimonious. The basic researchers who insist on proof of immune response prior to large clinical trials disagree with the vaccine researchers whose experience tells them that the proof of a vaccine's efficacy comes with those large clinical trials. The latter group maintains that many people don't understand the immune correlates of any vaccines currently in use and an AIDS vaccine is being held to a higher standard.

Some of those involved in policy issues question whether the National Institutes of Health, the nation's designated lead organization for direction of AIDS vaccine research, is up to this task or whether oversight should come from another direction--perhaps the White House Office of National AIDS Policy (ONAP).

No matter where people stand in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Myrna Watanabe

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours